This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga • 07/15/26
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong BuyZacks Investment Research • 07/08/26
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.The Motley Fool • 07/04/26
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock RallyThe Motley Fool • 06/27/26
This Top Biotech Has Surged. CEO Explains Key To Veracyte's Success.Investors Business Daily • 06/16/26
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer TranscriptSeeking Alpha • 06/01/26
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate CancerBusiness Wire • 05/30/26
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid ChemotherapyBusiness Wire • 05/29/26
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast CancerBusiness Wire • 05/21/26
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder CancerBusiness Wire • 05/15/26
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for InvestorsZacks Investment Research • 05/07/26